Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.

Literature DB >> 32567262

A Case of Breakthrough COVID-19 during Hydroxychloroquine Maintenance.

Byeong Yun Ahn¹, Chang Kyung Kang¹, Jong Do Seo², Pyoeng Gyun Choe¹, Sang Hoon Song², Wan Beom Park¹, Sang Won Park^1,3, Nam Joong Kim⁴, Myoung Don Oh¹.

Abstract

There have been controversies on the prophylactic effect of hydroxychloroquine against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). We describe a patient, 60-year old Korean woman, with coronavirus disease 2019 (COVID-19) who had been taking hydroxychloroquine for 6 months. Her serum and saliva concentrations of hydroxychloroquine were 280 μg/L and 4,890 μg/L, respectively. The present case raises concerns on hydroxychloroquine's role as a prophylactic agent for COVID-19.

Entities: Chemical Disease Gene Species

Keywords: COVID-19; Hydroxychloroquine; Prophylaxis; SARS-CoV-2

Mesh：

Substances：

Year: 2020 PMID： 32567262 PMCID： PMC7308141 DOI： 10.3346/jkms.2020.35.e231

Source DB: PubMed Journal: J Korean Med Sci ISSN： 1011-8934 Impact factor: 2.153

13 in total

Review 1. Methods of sputum processing for cell counts, immunocytochemistry and in situ hybridisation.

Authors: A Efthimiadis; A Spanevello; Q Hamid; M M Kelly; M Linden; R Louis; M M M Pizzichini; E Pizzichini; C Ronchi; F Van Overvel; R Djukanović
Journal: Eur Respir J Suppl Date: 2002-09

2. Determinants of hydroxychloroquine blood concentration variations in systemic lupus erythematosus.

Authors: M Jallouli; L Galicier; N Zahr; O Aumaître; C Francès; V Le Guern; F Lioté; A Smail; N Limal; L Perard; H Desmurs-Clavel; D Le Thi Huong; B Asli; J-E Kahn; J Pourrat; L Sailler; F Ackermann; T Papo; K Sacré; O Fain; J Stirnemann; P Cacoub; G Leroux; J Cohen-Bittan; J Sellam; X Mariette; B Blanchet; J S Hulot; Z Amoura; J C Piette; N Costedoat-Chalumeau
Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995

3. Multiple components contribute to ability of saliva to inhibit influenza viruses.

Authors: M R White; E J Helmerhorst; A Ligtenberg; M Karpel; T Tecle; W L Siqueira; F G Oppenheim; K L Hartshorn
Journal: Oral Microbiol Immunol Date: 2009-02

4. Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?

Authors: Sun Hee Lee; Hyunjin Son; Kyong Ran Peck
Journal: Int J Antimicrob Agents Date: 2020-04-17 Impact factor: 5.283

5. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.

Authors: Manli Wang; Ruiyuan Cao; Leike Zhang; Xinglou Yang; Jia Liu; Mingyue Xu; Zhengli Shi; Zhihong Hu; Wu Zhong; Gengfu Xiao
Journal: Cell Res Date: 2020-02-04 Impact factor: 25.617

6. In vitro activity of lopinavir/ritonavir and hydroxychloroquine against severe acute respiratory syndrome coronavirus 2 at concentrations achievable by usual doses.

Authors: Chang Kyung Kang; Moon-Woo Seong; Su-Jin Choi; Taek Soo Kim; Pyoeng Gyun Choe; Sang Hoon Song; Nam-Joong Kim; Wan Beom Park; Myoung-Don Oh
Journal: Korean J Intern Med Date: 2020-05-29 Impact factor: 2.884

7. Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Authors: Joshua Geleris; Yifei Sun; Jonathan Platt; Jason Zucker; Matthew Baldwin; George Hripcsak; Angelena Labella; Daniel K Manson; Christine Kubin; R Graham Barr; Magdalena E Sobieszczyk; Neil W Schluger
Journal: N Engl J Med Date: 2020-05-07 Impact factor: 91.245

8. COVID-19 infection also occurs in patients taking hydroxychloroquine.

Authors: M Lahouati; E Mériglier; L Martin; S Bouchet; A Desclaux; F Bonnet
Journal: J Antimicrob Chemother Date: 2020-07-01 Impact factor: 5.790

9. In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).

Authors: Xueting Yao; Fei Ye; Miao Zhang; Cheng Cui; Baoying Huang; Peihua Niu; Xu Liu; Li Zhao; Erdan Dong; Chunli Song; Siyan Zhan; Roujian Lu; Haiyan Li; Wenjie Tan; Dongyang Liu
Journal: Clin Infect Dis Date: 2020-07-28 Impact factor: 9.079

10. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro.

Authors: Jia Liu; Ruiyuan Cao; Mingyue Xu; Xi Wang; Huanyu Zhang; Hengrui Hu; Yufeng Li; Zhihong Hu; Wu Zhong; Manli Wang
Journal: Cell Discov Date: 2020-03-18 Impact factor: 10.849

2 in total

Review 1. Clinical Management of COVID-19: A Review of Pharmacological Treatment Options.

Authors: Ashli M Heustess; Melissa A Allard; Dorothea K Thompson; Pius S Fasinu
Journal: Pharmaceuticals (Basel) Date: 2021-05-28

Review 2. Benefits and adverse effects of hydroxychloroquine, methotrexate and colchicine: searching for repurposable drug candidates.

Authors: Durga Prasanna Misra; Armen Yuri Gasparyan; Olena Zimba
Journal: Rheumatol Int Date: 2020-09-02 Impact factor: 2.631

2 in total